VRTX Filings — Vertex Pharmaceuticals Inc / Ma - FilingSpy
VRTX
Vertex Pharmaceuticals Inc / Ma
A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.
Vertex Q2 2026 revenue rose 12.5% to $3.33B as ALYFTREK grew 266% to $573.6M
ALYFTREK more than tripled as TRIKAFTA/KAFTRIO slipped. rose 12.5% to $3,333.9M, rose 8.0% to $4.31, and fell 0.9 points to 85.3% as climbed 37% for new launches. Vertex is funding a $10.0B Crinetics acquisition with a $4.5B , adding integration risk to steady product growth.
Key takeaways
ALYFTREK revenues grew 266% to $573.6M in Q2 2026, partially offsetting a 2% decline in TRIKAFTA/KAFTRIO and lifting CF product revenues 11%.
Total revenues rose 12.5% to $3,333.9M and 11.6% from Q1, with CASGEVY up 151% and JOURNAVX up 313% from their early launch bases.
expenses rose 37% to $582.2M, driven by commercial investment for JOURNAVX and the anticipated povetacicept launch, while cost of sales rose to 14.7% of net product from 13.8% on product mix.
Section summaries
Management's Discussion and Analysis
Total revenues rose 12% to $3.3B in Q2 2026 driven by CF therapies and new product growth, while SG&A surged 37% for launches.
⌄
Total revenues increased 12% to $3.3B in Q2 2026, led by 11% growth in CF product revenues and strong contributions from CASGEVY and JOURNAVX.
The company entered a $4.5B to fund the planned $10.0B acquisition of Crinetics, and cash, equivalents, and marketable securities grew to $13.6B.
rose 8.0% to $4.31 and rose 8.3% to $1,246.9M versus a year ago, with no Alpine or charges this quarter.
The FDA accepted the povetacicept in IgAN with a of November 30, 2026, and two Phase 3 suzetrigine trials are expected to complete enrollment by year-end.
What changed
Q1 2026 flagged the 7% TRIKAFTA/KAFTRIO decline; in Q2 it narrowed to a 2% decline while ALYFTREK growth slowed to 266% from 687%, showing the shift toward ALYFTREK is continuing but at a decelerating pace.
FY 2025 flagged ALYFTREK label share capture through 2026; Q2 ALYFTREK reached $573.6M against TRIKAFTA/KAFTRIO's continued slight decline, confirming share capture is underway.
CASGEVY infusion volumes were flagged for Q2 2026; Q2 shows CASGEVY up 151% though the filing gives no patient-volume figure.
JOURNAVX trajectory against generics was flagged continuously; Q2 rose 313% to an undisclosed base, with up 37% to support it.
The Crinetics acquisition and its PALSONIFY/atumelnant dependence are new in this 10-Q's risk factors, not carried from the 2025 10-K, adding a material integration risk.
What to watch
Q3 2026 TRIKAFTA/KAFTRIO and whether the 2% decline widens or reverses as ALYFTREK grows.
Povetacicept FDA approval by the November 30, 2026 and its initial launch uptake.
Crinetics acquisition close, including antitrust clearance and the $4.5B draw.
Q3 2026 ALYFTREK net product and the label share it continues to take from TRIKAFTA/KAFTRIO.
ALYFTREK revenues grew 266% to $573.6M, partially offsetting a 2% decline in TRIKAFTA/KAFTRIO, while CASGEVY and JOURNAVX revenues rose 151% and 313%, respectively.
increased to 14.7% from 13.8% due to product mix changes, partially offset by a lower blended royalty rate for CF medicines.
SG&A expenses jumped 37% to $582.2M, primarily from increased headcount and commercial investment to support JOURNAVX and the anticipated launch of povetacicept.
Cash, cash equivalents, and marketable securities grew to $13.6B, and the company entered into a $4.5B term loan to fund the planned $10.0B acquisition of Crinetics.
The FDA accepted the BLA for povetacicept in IgAN with a PDUFA date of November 30, 2026, and the company expects to complete enrollment in two Phase 3 suzetrigine trials by year-end.
Quantitative and Qualitative Disclosures About Market Risk
Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February…
⌄
Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and
Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2025,
which was filed with the SEC on February 13, 2026.
Other than as described in Part I—Note L, “Commitments and Contingencies,” to our condensed consolidated financial statements, we are not currently subject to any material legal proceedings.
⌄
Other than as described in Part I—Note L, “Commitments and Contingencies,” to our condensed consolidated financial
statements, we are not currently subject to any material legal proceedings.